Introducing Gluetacs Therapeutics to the UK market
Gluetacs Therapeutics (www.gluetacs.com), a pioneering biotech company located in the innovative Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, is making significant strides in the field of targeted protein degradation, both in molecular glue (GLUE) and bifunctional degrader (GLUETAC). As a member of the Lingang Cambridge Network, Gluetacs is committed to advancing its cutting…
Cambridge Independent Business Awards 2024
We are thrilled to announce that Costello Medical won two prestigious awards at the inaugural Cambridge Independent Business Awards 2024! Congratulations to all the winners and finalists from the other categories and a big thank you to the Cambridge Independent for putting on such a wonderful gala at King’s College, Cambridge to celebrate the Cambridge business community’s successes!
FUJIFILM Irvine Scientific Adds Key Products To Its Life Sciences Portfolio From FUJIFILM Wako Chemicals U.S.A.
Additional products in lab automation, lab chemicals and LAL expand complete solutions available directly from FUJIFILM Irvine Scientific to customers in US and Europe Sales agreement aligns business and commercial operations to maximize customer benefit
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions
Axxam S.p.A. and Isogenica Ltd. have announced a partnership to bring together functional bioassay capabilities with unique antibody discovery solutions for biotechnology and pharmaceutical clients.
Hospital prosthetics service moves to high-tech new home
An Addenbrooke’s service that offers vital support for amputees and others officially opened on the 23rd Sept at a high-tech new home after nearly quarter of a century at the hospital.
Have a heart – learn CPR, says MP
In advance of World Heart Day, Daniel Zeichner, Member of Parliament for Cambridge, tried out RevivR, a new CPR training tool, at a British Heart Foundation (BHF) shop in Cambridge on Friday 20 September to highlight the charity's vital work in combating heart and circulatory diseases.
impulse’s next-gen female entrepreneurs eye up $1trillion FemTech sector
With the FemTech market set to be worth $1trillion by 2027 (McKinsey & Company), impulse, the University of Cambridge’s unique entrepreneurship programme, has seen a sharp rise in the number of participants contributing novel innovations to this exciting sector.
Transforming healthcare: the power of purpose-led partnerships
In this episode, Dr Bipin Patel sits down with Samuel Hollis, Coun
Enterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001
ETD001 is a novel, first in class blocker of the epithelial sodium channel (ENaC) aimed at treating people with cystic fibrosis without current effective therapies ETD001 commenced Phase 2 clinical trials in July 2024, expected to complete in 2025
Nxera Pharma receives approval of QUVIVIQ (daridorexant) in Japan for the treatment of insomnia
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpoints Plans to make QUVIVIQ available as soon as possible to insomnia patients in Japan are underway Tokyo, Japan and Cambridge, UK, 24 September 2024 – Nxera Pharma Co., Ltd. – formerly known as…
Takeda’s Qdenga® - more campaigns needed before single-dose products arrive
This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis publishes a brand-new global analysis of the dengue endemic vaccines market.
Steritas’ Pediatric Glucocorticoid Toxicity Index used by Alder Hey and Liverpool Trials Centre to assess steroid toxicity in children with juvenile idiopathic arthritis
Study will allow researchers to assess the outcomes of intravenous and oral glucocorticoid protocols in children
Broken String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Directors
Laurence Reid joins as Chairman, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Third Rock Ventures Brad Crutchfield appointed as Non-Executive Director, previously 10x Genomics, QIAGEN, Illumina, and Bio-Rad LaboratoriesC
Give your cleanroom the TLC it needs with Guardtech’s first-class decontamination programmes and elite furniture fit-outs
The Guardtech Group are urging clients to ensure their controlled environments are free of contamination and fully equipped to deliver the best results
Teaching the next generation of innovators...
Why does the planet need entrepreneurship? What can the next generation of innovators learn from big businesses?
Significant progress made in meeting demand for lab and office space
A joint news release on behalf of Cambridge City Council and South Cambridgeshire District Council and Greater Cambridge Shared Planning.
Mission Street and BGO get go-ahead for 23-acre central Cambridge science district
CAMBRIDGE, UK - In a significant step forward for the UK’s aspirations to be a ‘science superpower’, specialist investor, developer and operator for the science and innovation sector Mission Street and BGO, a leading global real estate investment manager, received planning consent to deliver a world-class 23-acre urban science district in central Cambridge.
FUJIFILM Irvine Scientific develops Oceo Rover: the first automated single-use hydration system for media and buffers
Oceo Rover automates and simplifies hydration of powdered media and buffers, to optimize bioprocessing workflows Automated system harnesses single-use technology to reduce risks associated with variability, contamination and safety within biopharmaceutical manufactur
New state-of-the-art radiotherapy equipment benefiting patients in the East
Cancer patients undergoing treatment at Norfolk and Norwich University Hospital’s NHS Foundation Trust (NNUH) and Cambridge University Hospitals NHS Foundation Trust (CUH) are benefiting from a new type of radiotherapy which reduces treatment time whilst increasing accuracy and patient comfort.
Breast and ovarian cancer newly linked to thousands of gene variants
Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer, paving the way for better risk assessment and more personalised care.
Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development
High performance two-plasmid production system achieves E12 vg/mL unconcentrated titers AI-driven design tools to improve expression precision, efficacy, and manufacturabilityBoston, Massachusetts, 18 Sep 2024: Asimov, the synth
Living with ILD: A typical patient journey
Interstitial lung diseases (ILDs) are a group of disorders characterised by scarring and inflammation of the lung interstitium, common examples of which include idiopathic pulmonary fibrosis (IPF)and sarcoidosis.
PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease
Project evaluated small molecules against novel target in coronary artery disease discovered by PlaqueTec Bespoke cell-based assay developed by RxCelerate to test small molecules predicted to bind candidate targetCambridge, UK, 18 Septem
Cambridge Enterprise appoints new Chief Executive
Dr Jim Glasheen has been appointed as Chief Executive of Cambridge Enterprise, the innovation arm of the University of Cambridge. Dr Glasheen will assume his post later in 2024.
OpticFlock – helping chicken producers to achieve welfare and efficiency
With Oxford Computer Consultants (part of System C) expertise, the University of Oxford have been working towards realising the potential of their research correlating flock movement and chickens’ underlying health conditions such as lameness and infection.